Nurix Therapeutics shares are trading higher after HC Wainwright & Co. maintained a Buy rating and raised its price target from $19 to $26.
Portfolio Pulse from Benzinga Newsdesk
Nurix Therapeutics shares are trading higher after HC Wainwright & Co. maintained a Buy rating and raised its price target from $19 to $26.
June 18, 2024 | 4:54 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Nurix Therapeutics shares are trading higher following HC Wainwright & Co.'s decision to maintain a Buy rating and raise the price target from $19 to $26.
The increase in price target and the maintained Buy rating from a reputable analyst firm like HC Wainwright & Co. is likely to boost investor confidence and drive the stock price higher in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100